Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: ALS
Interventions: Riluzole Oral Soluble Film; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab plus Early Vaccination, Belimumab plus Late Vaccination; Biological
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Conditions: Metastatic Colorectal Cancer
Interventions: Sym004; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Major Depressive Disorder
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fentanyl citrate, pharmacological study; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Incisional Hernia
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema
Interventions: Faricimab; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more

Conditions: Relapsed / Refractory Osteosarcoma
Interventions: LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Coronary Disease, Diabetes Mellitus
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 15,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more

Conditions: Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions: SB497115, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Healthy Volunteer
Interventions: Placebo, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Eatontown, New Jersey

Conditions: Covid19
Interventions: Hyperbaric Oxygen Therapy (HBOT); Device
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Bozeman, Montana • Mineola, New York • Portland, Oregon

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more

Conditions: Synechia
Interventions: MediENT, MeroPack; Device
Lead sponsor: ENTrigue Surgical, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Fresno, California • Colorado Springs, Colorado • Louisville, Kentucky + 2 more

Conditions: Kidney Cancer, Ureteral Cancer, Prostate Cancer, Nephrolithiasis
Interventions: telerounding versus bedside rounding; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Sacramento, California • Baltimore, Maryland • Norfolk, Virginia

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Interventions: Angiogram, Biospecimen Collection, Computed Tomography, Radioembolization, Single Photon Emission Computed Tomography, Survey Administration, Yttrium Y 90 Glass Microspheres; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Los Angeles, California • Aurora, Colorado

Conditions: Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
Interventions: Droxidopa, Carbidopa, Entacapone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nasolabial Folds
Interventions: Sculptra Aesthetic 8ml, Sculptra Aesthetic 5ml; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 2 more

Conditions: Lupus Nephritis
Interventions: LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid; Drug · Biological
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 27
States / cities: La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more

Conditions: Prostate Cancer
Interventions: Whole-food, Plant-Based Diet, General Nutritional Counseling; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 99 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Search by objective public record fields.

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Sym004 in Patients With Advanced Solid Tumors

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Studying Fentanyl in Patients With Cancer

Incisional Hernia Outcomes Study Using Parietex Composite Mesh

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

A Prospective, Randomized, Multi-Center Evaluation of MediENT® Middle Turbinate Implant Versus MeroPack®, a Bioresorbable Nasal Dressing / Sinus Stent After Endoscopic Sinus Surgery

Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction.

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping